The Japanese pharmaceutical company Eisai is expanding the geographical reach of its UK headquarters in Hatfield, Hertfordshire, to support its growing European, Middle Eastern and African (EMEA) businesses.
The move is expected to create more jobs at the company’s £100m facility, which opened in 2009.
Gary Hendler, president and CEO of the EMEA regions at Eisai, said: “Our new UK-based EMEA hub will . . . [improve] knowledge interaction across the region, including shared pricing/reimbursement strategies and the transmission of medical and marketing knowledge.”
The expansion is part of the company’s plan to secure its presence in the top 20 pharmaceutical market regions by 2015.
Hendler added: “Eisai has been successfully operating in Europe for more than 20 years and we are deeply proud to be expanding our efforts to increase access to medicines based on a long-term sustainable strategy to improve affordability, availability and adoption.”
In Europe, Eisai undertakes sales and marketing operations in over 20 markets, including the UK, France, Germany and Austria.
“We chose to base our EMEA operations in the UK as we recognise the country's importance as a global hub for the pharmaceutical industry. Initiatives to support the life-sciences sector championed by the Department of Business, Innovation and Skills have added to our ability to cure and care for the health and well-being of more people across the EMEA region,” concluded Hendler.
Earlier in 2012, Eisai signed a declaration with the Bill & Melinda Gates Foundation, the WHO, the World Bank and several governments to make a co-ordinated effort to eliminate ten neglected tropical diseases by 2020.